# Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

> **NCT06263543** · PHASE2 · RECRUITING · sponsor: **Reshma L. Mahtani, D.O.** · enrollment: 75 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Human Epidermal Growth Factor 2 Low Breast Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06263543
- **Lead sponsor:** Reshma L. Mahtani, D.O.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263543, "Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06263543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*